<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>04255597805705</udiDi>
    <basicUdiDi>42555978ANTIBODYG00649</basicUdiDi>
    <tradeName>Granzyme B (QR130)</tradeName>
    <deviceName>Granzyme B (QR130)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-G006-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:19.879Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805569</udiDi>
    <basicUdiDi>42555978ANTIBODYE0073V</basicUdiDi>
    <tradeName>EMA (QR118)</tradeName>
    <deviceName>EMA (QR118)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-E007-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:19.086Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805286</udiDi>
    <basicUdiDi>42555978ANTIBODYC0483V</basicUdiDi>
    <tradeName>CDK4 (QR115)</tradeName>
    <deviceName>CDK4 (QR115)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C048-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:18.279Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805491</udiDi>
    <basicUdiDi>42555978ANTIBODYC0513J</basicUdiDi>
    <tradeName>Cytokeratin 19 (QR125)</tradeName>
    <deviceName>Cytokeratin 19 (QR125)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C051-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:17.528Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805422</udiDi>
    <basicUdiDi>42555978ANTIBODYC0543Q</basicUdiDi>
    <tradeName>Cytokeratin 18 (QR147)</tradeName>
    <deviceName>Cytokeratin 18 (QR147)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C054-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:16.700Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805354</udiDi>
    <basicUdiDi>42555978ANTIBODYC0463R</basicUdiDi>
    <tradeName>CEA (QR117)</tradeName>
    <deviceName>CEA (QR117)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C046-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:15.876Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805217</udiDi>
    <basicUdiDi>42555978ANTIBODYC0453P</basicUdiDi>
    <tradeName>CD68 (QR105)</tradeName>
    <deviceName>CD68 (QR105)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C045-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:14.280Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805149</udiDi>
    <basicUdiDi>42555978ANTIBODYC0503G</basicUdiDi>
    <tradeName>CD1a (QR123)</tradeName>
    <deviceName>CD1a (QR123)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C050-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:13.470Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805071</udiDi>
    <basicUdiDi>42555978ANTIBODYC0533N</basicUdiDi>
    <tradeName>Calponin 1 (QR139)</tradeName>
    <deviceName>Calponin 1 (QR139)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C053-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:12.690Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597805002</udiDi>
    <basicUdiDi>42555978ANTIBODYB00534</basicUdiDi>
    <tradeName>BAP1 (QR119)</tradeName>
    <deviceName>BAP1 (QR119)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-B005-050</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:11.872Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804937</udiDi>
    <basicUdiDi>42555978ANTIBODYA0062X</basicUdiDi>
    <tradeName>Androgen receptor (QR135)</tradeName>
    <deviceName>Androgen receptor (QR135)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-A006-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:11.076Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804869</udiDi>
    <basicUdiDi>42555978ANTIBODYC01034</basicUdiDi>
    <tradeName>Cytokeratin pan (QR124)</tradeName>
    <deviceName>Cytokeratin pan (QR124)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C010-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:10.274Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804791</udiDi>
    <basicUdiDi>42555978ANTIBODYI0104E</basicUdiDi>
    <tradeName>INSM1 (QR128)</tradeName>
    <deviceName>INSM1 (QR128)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-I010-01</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:09.478Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804234</udiDi>
    <basicUdiDi>42555978ANTIBODYC0183L</basicUdiDi>
    <tradeName>c-Myc (QR061)</tradeName>
    <deviceName>c-Myc (QR061)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C018-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:08.672Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804098</udiDi>
    <basicUdiDi>42555978ANTIBODYS0066V</basicUdiDi>
    <tradeName>STAT6 (QR041)</tradeName>
    <deviceName>STAT6 (QR041)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-S006-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:07.878Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803954</udiDi>
    <basicUdiDi>42555978ANTIBODYN0035L</basicUdiDi>
    <tradeName>NKX3.1 (QR055)</tradeName>
    <deviceName>NKX3.1 (QR055)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N003-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:07.087Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803886</udiDi>
    <basicUdiDi>42555978ANTIBODYP01467</basicUdiDi>
    <tradeName>PSA (QR038)</tradeName>
    <deviceName>PSA (QR038)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P014-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:06.285Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803398</udiDi>
    <basicUdiDi>42555978ANTIBODYA0042T</basicUdiDi>
    <tradeName>AMACR (QR108)</tradeName>
    <deviceName>AMACR (QR108)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-A004-01</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:05.476Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803312</udiDi>
    <basicUdiDi>42555978ANTIBODYC00235</basicUdiDi>
    <tradeName>CD3e (QR004)</tradeName>
    <deviceName>CD3e (QR004)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C002-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:04.686Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803244</udiDi>
    <basicUdiDi>42555978ANTIBODYC0063D</basicUdiDi>
    <tradeName>CD10 (QR021)</tradeName>
    <deviceName>CD10 (QR021)</deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-C006-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-01T19:16:03.873Z</lastUpdated>
  </row>
</eudamedExport>